C-reactive Protein Treatment

Any therapy to lower c-reactive protein levels focuses on lowering the cardiovascular risk factors. Regular exercise, appropriate diet, and smoking cessation are in the forefront of cardiovascular risk prevention and reduction.

Cholesterol-lowering medications (statins) have been linked to lowering of c-reactive protein levels in individuals with high cholesterol. The fall of c-reactive protein levels may occur even without significant improvement in cholesterol levels.

The use of aspirin in healthy individuals was not shown to reduce c-reactive protein levels significantly. However, in patients with cardiovascular disease and elevated c-reactive protein, the reduction of cardiovascular risk and c-reactive protein levels was noted after aspirin use.

Some oral diabetes medicines, thiazolidinediones [rosiglitazone (Avandia) and pioglitazone (Actos), were noted to reduce c-reactive protein levels in patients with or without type 2 diabetes. This effect was independent of their glucose-lowering effects.